Avrobio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AVRO Nasdaq 8731 http://www.avrobio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avrobio Inc

AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update - Mar 23rd, 2023 11:00 am
AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference - Mar 3rd, 2023 12:00 pm
AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023 - Feb 9th, 2023 12:00 pm
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 5th, 2023 12:00 pm
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy - Dec 7th, 2022 12:30 pm
AVROBIO to Share Comprehensive Gaucher Disease Program Update - Nov 17th, 2022 12:00 pm
AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 8th, 2022 12:00 pm
AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit - Nov 7th, 2022 12:00 pm
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 3rd, 2022 11:00 am
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease - Oct 27th, 2022 11:00 am
AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis - Oct 25th, 2022 11:00 am
AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease - Oct 18th, 2022 11:00 am
AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development - Oct 11th, 2022 11:00 am
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress - Sep 27th, 2022 11:00 am
AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis - Sep 20th, 2022 11:00 am
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial - Sep 14th, 2022 11:28 am
AVROBIO to Participate in Four Upcoming Investor Conferences in September - Aug 31st, 2022 11:00 am
AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update - Aug 9th, 2022 11:00 am
AVROBIO to Participate in Two Upcoming Investor Conferences in August - Aug 1st, 2022 11:00 am
AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome - Jul 13th, 2022 11:00 am